Zenas BioPharma (ZBIO) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $45.00 | Aug 14, 2026 |
| Guggenheim | Maintained | Buy | $55.00 | Aug 14, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $32.00 from $22.00 | Aug 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $44.00 | May 15, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $22.00 from $21.00 | May 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $44.00 | Mar 17, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $21.00 from $19.00 | Mar 17, 2026 |
| Guggenheim | Maintained | Buy | $55.00 from $45.00 | Mar 17, 2026 |
| Citigroup | Maintained | Buy | $41.00 from $43.00 | Mar 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $44.00 | Feb 10, 2026 |
| Morgan Stanley | Downgraded | Overweight → Equal-Weight | $19.00 from $37.00 | Jan 6, 2026 |
| Wedbush | Maintained | Outperform | $45.00 | Dec 22, 2025 |
| Evercore ISI Group | Initiated Coverage | Outperform | $55.00 | Nov 26, 2025 |
| Morgan Stanley | Maintained | Overweight | $37.00 from $34.00 | Nov 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $44.00 from $30.00 | Oct 28, 2025 |
| Morgan Stanley | Maintained | Overweight | $34.00 from $31.00 | Oct 28, 2025 |
| Citigroup | Maintained | Buy | $46.00 from $27.00 | Oct 28, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 | Oct 9, 2025 |
| Wedbush | Maintained | Outperform | $40.00 from $35.00 | Oct 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 | May 16, 2025 |
Frequently asked questions
What is the price target for ZBIO stock?
The average 12-month analyst price target for Zenas BioPharma (ZBIO) is $44.00, with a high estimate of $55.00 and a low of $32.00, across 3 analysts.
Is ZBIO a buy, sell, or hold?
Analysts covering Zenas BioPharma currently average a Buy rating: 7 buy, 1 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ZBIO?
The average price target of $44.00 implies 39.42% upside from the last price of $31.56.
What is the latest analyst rating on ZBIO?
On Aug 14, 2026, Wedbush maintained Zenas BioPharma at Outperform with a price target of $45.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.